Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 5/20 | 0.33 |
| ▸ | CTSL | P07711 | 5/20 | 0.33 |
| ▸ | CTSB | P07858 | 4/20 | 0.33 |
| ▸ | CTSK | P43235 | 6/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PPIA | P62937 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13691651 | 0.89 | CTSK (0.33) | RORCCTSSCTSLCTSBCTSK | |
| SCHEMBL13691428 | 0.88 | RORC (0.34) | RORCCTSSCTSLCTSBCTSK | |
| SCHEMBL9921563 | 0.87 | TLR2 (0.35) | RORCCTSSCTSLCTSBCTSK | |
| SCHEMBL52246 | 0.82 | HPGD (0.37) | RORCCTSSCTSLCTSBCTSK | |
| SCHEMBL14214194 | 0.77 | TSHR (0.38) | RORCCTSSCTSLCTSBCTSK | |
| SCHEMBL63621 | 0.77 | ROCK2 (0.38) | RORCCTSSCTSLCTSBCTSK | |
| SCHEMBL9905103 | 0.77 | RORC (0.36) | RORCCTSSCTSLCTSBCTSK | |
| SCHEMBL62281 | 0.76 | KCNH2 (0.42) | ALDH1A1 | |
| SCHEMBL9905086 | 0.75 | HPGD (0.39) | RORCADORA2AADORA1 | |
| SCHEMBL14214193 | 0.75 | TSHR (0.36) | RORCCTSSCTSLCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| WO-2009117540-A1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253677-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | RORC 1817/4885CTSS 3030/4885CTSL 3453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.